Leerink Partners Maintains a Hold on Amgen (AMGN)

Amgen Inc. (NASDAQ:AMGN) is one of the best affordable growth stocks to buy. Leerink Partners analyst David Risinger maintained their neutral stance on Amgen Inc. (NASDAQ:AMGN) on August 26, giving the stock a Hold rating.

The analyst told investors in a research note that he expects the recent approval of Repatha’s expanded label to boost its market penetration, especially in the primary prevention space for cardiovascular events.

However, he added that the current market penetration remains low despite this positive development, with the immediate opportunity depending more on the rising treatment urgency instead of expansion in the patient base.

Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures, and markets human therapeutics. It delivers new therapies for patients with complex cancers, especially in areas with significant unmet needs.

While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.